This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Ribociclib
From Proteopedia
(Difference between revisions)
| (One intermediate revision not shown.) | |||
| Line 1: | Line 1: | ||
| - | <StructureSection load='' size='340' side='right' caption=' | + | <StructureSection load='' size='340' side='right' caption='Ribociclib' scene='10/1004490/Cv/2'> |
Ribociclib, sold under the brand name Kisqali, is a medication used for the treatment of certain kinds of breast cancer. Ribociclib inhibits the enzymes [[Cyclin Dependent Kinase-4|cyclin-dependent kinase 4]] (CDK4) and cyclin-dependent kinase 6 (CDK6).<ref name="a7">[https://www.hcp.novartis.com/products/kisqali/metastatic-breast-cancer/ "Kisqali (ribociclib) Treatment: HR+/HER2- mBC". Novartis. Retrieved 24 August 2021.]</ref> See also [https://en.wikipedia.org/wiki/Ribociclib Ribociclib] and [[CDK4]]. | Ribociclib, sold under the brand name Kisqali, is a medication used for the treatment of certain kinds of breast cancer. Ribociclib inhibits the enzymes [[Cyclin Dependent Kinase-4|cyclin-dependent kinase 4]] (CDK4) and cyclin-dependent kinase 6 (CDK6).<ref name="a7">[https://www.hcp.novartis.com/products/kisqali/metastatic-breast-cancer/ "Kisqali (ribociclib) Treatment: HR+/HER2- mBC". Novartis. Retrieved 24 August 2021.]</ref> See also [https://en.wikipedia.org/wiki/Ribociclib Ribociclib] and [[CDK4]]. | ||
| Line 7: | Line 7: | ||
<scene name='10/1004490/Cv/3'>The X-ray co-crystal structure of human CDK6 and Ribociclib</scene> ([[5l2t]]). | <scene name='10/1004490/Cv/3'>The X-ray co-crystal structure of human CDK6 and Ribociclib</scene> ([[5l2t]]). | ||
| + | |||
| + | <scene name='10/1004490/Binding_site/1'>Ribociclib binding ite</scene>. | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Current revision
| |||||||||||
References
- ↑ "Kisqali (ribociclib) Treatment: HR+/HER2- mBC". Novartis. Retrieved 24 August 2021.
- ↑ 2.0 2.1 doi: https://dx.doi.org/10.1097/01.COT.0000444043.33304.c1
- ↑ doi: https://dx.doi.org/10.1158/1535-7163.TARG-13-PR02
- ↑ doi: https://dx.doi.org/10.1200/jco.2014.32.15_suppl.9009
- ↑ doi: https://dx.doi.org/10.1158/1538-7445.AM2014-1000
